Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 93 Show results per page	View Search Criteria \| Help With Results


1.		Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				75 and under				Other				Pethema LPA-99 protocol NCT00465933

Last Modified: 2/26/2008 First Published: 6/1/1995


2.		Phase III Randomized Study of Two Induction Courses That Include Daunorubicin vs Mitoxantrone and Filgrastim (G-CSF) vs Placebo, Followed By MACE (Amsacrine, Cytarabine, and Etoposide), Then Bone Marrow Transplantation (BMT) vs MidAC (Mitoxantrone and Cytarabine) vs ICE (Idarubicin, Cytarabine, and Etoposide) Followed By BMT vs ICE Followed By MidAC in Patients With Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to physiologic 59				Other				MRC-LEUK-AML12 EU-95001, NCT00002658

Last Modified: 11/29/2006 First Published: 1/1/1996


3.		Phase III Randomized Study of Induction Using Tretinoin (ATRA) and Idarubicin (IDA), 3 Sequential Consolidation Regimens Using Cytarabine Plus IDA, Followed by Mitoxantrone Plus Etoposide, and then IDA, Cytarabine, and Thioguanine, and Maintenance Using Mercaptopurine (MP) Plus Methotrexate (MTX) Versus ATRA Only Versus MP Plus MTX Alternating With ATRA Versus Observation Only With or Without Bone Marrow Transplantation in Patients With Acute Promyelocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 to 74								EORTC-06952 ITA-GIMEMA-AIEOP-1, NCT00002701

Last Modified: 8/1/1997


4.		Phase III Randomized Study of Tretinoin for 5 Days Prior to Induction Chemotherapy vs Continuous Tretinoin Beginning Concurrently with Induction Chemotherapy for Acute Promyelocytic Leukemia (Summary Last Modified 08/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				any age								MRC-LEUK-ATRA EU-95038

Last Modified: 4/1/1998 First Published: 12/1/1997


5.		Phase III Study of 9-cis-Retinoic Acid versus Tretinoin in Patients with Newly Diagnosed Acute Promyelocytic Leukemia (Summary Last Modified 04/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				LIGAND-L1057-77 NCI-V97-1291

Last Modified: 10/6/2008 First Published: 8/1/1999


6.		Phase III Randomized Study of Tretinoin, Cytarabine, and Daunorubicin With or Without Arsenic Trioxide as Induction/Consolidation Therapy Followed by Intermittent Tretinoin With or Without Mercaptopurine and Methotrexate as Maintenance Therapy in Patients With Previously Untreated Acute Promyelocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				NCI				CALGB-C9710 CAN-NCIC-AL3, COG-C9710, ECOG-C9710, SWOG-C9710, CAN-NCIC-C9710, C9710, NCT00003934, AL3

Last Modified: 12/10/2007 First Published: 6/1/2000


7.		Phase III Randomized Study of Intensive Versus Nonintensive Chemotherapy in Older Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				60 and over				Other				LRF-AML14 EU-20016, NCT00005823, ISRCTN62207270

Last Modified: 7/11/2007 First Published: 6/1/2000


8.		Phase III Randomized Study of Induction Chemotherapy With Cytarabine, Daunorubicin, and Etoposide Versus Fludarabine and Cytarabine and Induction Chemotherapy With Versus Without Filgrastim (G-CSF) or Tretinoin in Patients With High Risk Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				Other				MRC-LEUK-AML-HR EU-20008, NCT00005863

Last Modified: 6/12/2008


9.		Phase III Randomized Trial of Tretinoin vs ARA-C/DNR as Induction Therapy and of Tretinoin vs Observation as Maintenance Therapy for Patients with Previously Untreated Promyelocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				any age				NCI				E-2491 ALSG-91/M5, CAN-NCIC-AL2, CCG-2911, CLB-9191, POG-9220, SWOG-9129, EST-2491, INT-0129, E2491, BL10

Last Modified: 12/1/1992


10.		Phase III Randomized Study of IFN-A vs IFN-A/TRA in Patients with CML in Chronic Phase (Summary Last Modified 12/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over								MSKCC-92017A1 NCI-V92-0096

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute